Novartis Pharma AG: Novartis receives positive CHMP opinion for Tabrecta for patients with METex14 advanced non-small cell lung cancer

Opinion based on Phase II GEOMETRY mono-1 study showing an overall response rate (ORR) of 51.6% in a cohort evaluating second-line patients only and 44% in all previously-treated patients with advanced

Related Keywords

Germany ,Japan ,United States ,Switzerland ,Chicago ,Illinois ,America ,American ,Juergen Wolf ,Isabella Zinck ,Le Mouhaer ,Veronique Boissonnas ,Nicole Zinsli Somm ,Samir Shah ,Parag Mahanti ,Julie Masow ,Sloan Simpson ,Alina Levchuk ,Global Oncology Communications ,American Society Of Clinical Oncology ,Twitter ,European Commission ,World Health Organization ,University Hospital Cologne ,Novartis Us External Communications ,Novartis External Communications ,Novartis ,Exchange Commission ,Innovative Medicines International ,European Union ,European Medicines Agency ,Committee For Medicinal Products Human Use ,American Cancer Society ,Medicinal Products ,Human Use ,Integrated Oncology ,Clinical Oncology ,Annual Meeting ,Marie France Tschudin ,Chief Commercial Officer ,Blinded Independent Review Committee ,Disease Control Rate ,Accessed March ,Oncology Communications ,Dharma ,Eceives ,Positive ,Thmp ,Opinion ,Abrecta ,Patients ,Etex14 ,Dvanced ,Mall ,Fell ,Young ,Dancer ,